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AZD5363 was generally predictive of multiple-dose phar-
macokinetics. Confirmed partial responses were reported 
by two patients, both of whom were Akt1 (E17K) mutation 
positive. One patient in the 480 mg bid 4/3 dosing cohort 
maintained partial response for >2 years.
Conclusions Intermittent dosing of AZD5363 was more 
tolerable than continuous dosing. 480 mg bid intermittent 
4/3 dosing for AZD5363 monotherapy was selected for fur-
ther investigation. Preliminary evidence of antitumor activ-
ity was observed. Akt1 (E17K) is a potent driver mutation 
that may predict clinical response to AZD5363.
Keywords AZD5363 · Akt inhibitor · Safety · Solid 
tumor · Akt1 (E17K) mutation
Introduction
The PI3K/Akt/mTOR signaling pathway is an attrac-
tive target for anticancer therapies given its crucial role in 
tumor progression [1]. Akt is an important signaling node 
within this pathway, promoting tumorigenesis and metas-
tasis and inhibiting apoptosis [2]. Aberrant Akt signaling is 
associated with anticancer drug resistance, and inhibition 
of Akt is known to confer susceptibility to various treat-
ment modalities, such as chemotherapy and radiotherapy 
[3, 4]. To date, monotherapeutic interventions targeting the 
PI3 K/Akt/mTOR pathway have been generally unsuccess-
ful [5], likely because of incomplete target inhibition or 
compensatory feedback loops that lead to drug resistance 
[5]. More effective inhibitors of the PI3K/Akt/mTOR path-
way administered to appropriately selected patients or in 
more biologically relevant combinations are required.
AZD5363, a potent, selective inhibitor of Akt, has dem-
onstrated antitumor activity by overcoming or delaying 
Abstract 
Purpose Investigate the safety and tolerability of 
AZD5363 and define a recommended dose for evaluation 
in Japanese patients with advanced solid malignancies.
Methods AZD5363 was administered orally as a single 
dose, and then the dose was escalated to twice daily (bid) 
in separate continuous (every day) and intermittent (4 days 
on, 3 days off [4/3] or 2 days on, 5 days off [2/5]) dosing 
schedules to reach recommended doses defined by dose-
limiting toxicity (DLT). Doses for continuous, 4/3, and 2/5 
intermittent dosing schedules were 80–400, 360–480, and 
640 mg, respectively, and were informed by results from an 
equivalent study in Caucasian patients.
Results Forty-one patients received AZD5363. DLTs 
were only experienced with continuous dosing. 97.6 % 
of patients reported at least one adverse event (AE); most 
common were diarrhea (78.0 %), hyperglycemia (68.3 %), 
nausea (56.1 %), and maculopapular rash (56.1 %). Grade 
≥3 AEs were reported by 63.4 % of patients. Exposure of 
AZD5363 was generally dose proportional for both sin-
gle and multiple doses. Single-dose pharmacokinetics of 
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resistance to pharmacological therapies in several cancer 
xenograft models [6]. A first inpatient study has evaluated 
AZD5363 administered to Western patients with advanced 
solid malignancies (AstraZeneca study D3610C00001, 
NCT01226316) [7]. Patients received escalating doses 
of AZD5363 in separate dosing regimens, either continu-
ous twice daily (bid) every day or intermittent (4 days on, 
3 days off [4/3]), in order to establish the maximum toler-
ated dose (MTD). From these studies, a recommended dose 
of 480 mg bid was determined for AZD5363 monotherapy 
in a 4/3 dosing schedule.
Objectives of the current study were to investigate the 
safety and tolerability of AZD5363 and to define a recom-
mended dose for further clinical evaluation when given 
either continuously (bid dosing every day) or intermittently 
(4/3 or 2 days on, 5 days off [2/5]) to Japanese patients 
with advanced solid malignancies. This study is registered 




Patients aged ≥20 years with histological or cytological 
confirmation of a solid malignant tumor refractory to stand-
ard therapies or with no suitable effective standard treat-
ments, as well as a World Health Organization (WHO) per-
formance status of 0–1, were eligible for study inclusion.
The study was approved by an independent ethics com-
mittee and complied with the International Conference of 
Harmonisation Harmonised Tripartite Guidelines for Good 
Clinical Practice, the Declaration of Helsinki, local laws, 
and the AstraZeneca policy on bioethics [8]. All patients 
provided written informed consent.
Study design and treatment
This was a phase 1, open-label, multicenter, dose escala-
tion study. For the first cohort, each patient received a sin-
gle 80-mg dose of AZD5363 within 7 days of screening 
(cycle 0) followed by 3–7 days of washout. All doses were 
required to be taken in a fasted state (no caloric intake from 
2 h before dosing to 1 h after dosing). A continuous dosing 
regimen (cycle 1) was then initiated, with patients receiving 
AZD5363 bid every day.
All evaluations during the bid dosing regimen were 
conducted in 21-day assessment cycles. Patients were 
enrolled to ensure a minimum of three and a maximum of 
six evaluable patients per cohort. Dose escalation and de-
escalation were determined by the number of dose-limiting 
toxicities (DLTs; defined as any toxicity related to study 
drug as assessed by the investigator and not attributable 
to the disease under investigation) in a cohort. If no DLT 
was observed in a cohort of 3–6 evaluable patients, the dose 
could be escalated. If one patient in a group of >3 evalu-
able patients experienced a DLT, the cohort was expanded 
to include six evaluable patients. If only one DLT was 
observed in the complete cohort of six evaluable patients, 
the dose could then be escalated. If ≥2 patients in a group of 
up to six evaluable patients experienced a DLT, irrespective 
of the number of patients enrolled, the dose was considered 
not tolerated and recruitment to the cohort and dose escala-
tion was ceased. De-escalation to a lower intermediary dose 
could be considered in order to better define the MTD.
Based on emerging clinical data from the continuous 
dosing regimen of this study and data from the Western 
Study 1 (D3610C00001, NCT01226316), which was run-
ning in parallel with the Japanese study, an intermittent 
dosing regimen was also evaluated in Japanese patients 
and with a starting dose of 480 mg bid and a 4/3 dosing 
schedule.
The primary objective of the study was to investigate the 
safety and tolerability of escalating doses of AZD5363 in 
order to define a recommended dose in Japanese patients 
with advanced solid tumors. Secondary objectives included 
characterizing the pharmacokinetics (PK) of AZD5363 
and a preliminary assessment of the antitumor activity of 
AZD5363 monotherapy.
Assessments
Safety and tolerability were assessed in terms of adverse 
events (AEs), serious adverse events (SAEs), deaths, labo-
ratory data, vital signs, electrocardiogram (ECG), assess-
ment of glucose metabolism, and physical examination. 
AEs were graded according to the Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0. Any AE 
occurring after the first dose of study treatment and within 
30 days of the last dose of study treatment was included in 
the AE summaries.
For PK analyses, plasma concentrations of AZD5363 
were assessed up to 48 h after a single dose. After multi-
ple doses, plasma concentrations were assessed up to 12 h 
on days 2, 4, and 8 for the 2/5 and 4/3 intermittent dosing 
and continuous dosing schedules, respectively. Single-dose 
PK parameters assessed included area under the plasma 
concentration–time curve (AUC), maximum plasma (peak) 
drug concentration (Cmax), time to reach Cmax (tmax), appar-
ent plasma clearance (CL/F), and oral volume of distribu-
tion at steady state (Vss/F). Steady-state PK parameters 
included AUCss, Css,max, tss,max, and CLss/F.
Objective tumor response assessments were based on 
Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.1.
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Tumor samples were screened for mutations using a 
clinical sequencing platform consisting of an in-house can-
cer gene panel (National Cancer Center OncoPanel version 
2) based on an Agilent Sure Select system and an Illumina 
MiSeq sequencer. The target regions to be captured were 
the exons of 90 targetable or actionable genes and the 
introns of 10 protein kinase genes. Samples with <10 % 
tumor cell content were excluded from the analysis.
Statistical analyses
Data were summarized using descriptive statistics, and no 
formal statistical analyses of the primary or secondary end-
points were performed. Patients were grouped by schedule 
and dose. All calculations were performed with the SAS® 
software, version 9.1.3 or higher.
The safety and PK analysis sets comprised all patients who 
received at least one dose of AZD5363 and all patients who 
provided concentration–time data for AZD5363, respectively.
Results
Patient characteristics
Fifty-two patients were enrolled in the study, of which 41, all 
of Japanese ethnicity, received AZD5363 and were evaluable 
for safety analyses. Of these patients, 39 discontinued study 
treatment (data cutoff July 7, 2014), 27 of whom did so as 
a result of worsening of the condition under investigation, 
with the remainder owing to patient decision to discontinue 
(N = 6), adverse events (N = 5), and protocol non-compli-
ance (N = 1). There was one protocol deviation that was 
considered to be important (one patient did not fulfill eligi-
bility criteria because of a familial history of long QT syn-
drome—this patient was withdrawn from the study on Day 9 
of Cycle 0) in the 360 mg bid intermittent 4/3 dosing cohort.
The overall demographic and disease baseline character-
istics of the study population were considered representa-
tive of the target population and are summarized in Table 1. 
There were 24 females (58.5 %) and 17 males (41.5 %), 
with a mean age of 52.0 years (range: 27–73 years). Breast 
cancer (19.5 %) was the most common primary tumor. 
With the exception of one patient, all had metastatic dis-
ease at baseline (97.6 %). Prior to study entry, all patients 
had received ≥1 chemotherapy regimen, while 78.1 % had 
received ≥3 chemotherapy regimens (median number of 
prior chemotherapy regimens was 4.0 [range: 1–8]).
Safety and tolerability outcomes
In the safety analysis set, 97.6 % of patients experienced 
at least one AE, of which 95.1 % were judged by the local 
investigator to be related to AZD5363 (Table 2). Overall, 
the most frequently reported AEs were diarrhea (78.0 %), 
hyperglycemia (68.3 %), nausea (56.1 %), and maculo-
papular rash (56.1 %). A total of 63.4 % of patients expe-
rienced an AE of CTCAE grade ≥3, with hyperglycemia 
(39.0 %) and diarrhea (17.1 %) being the most common; 
58.5 % of patients experienced a grade ≥3 AE considered 
to be treatment related. Discontinuations due to an AE 
occurred in 12.2 % of patients, while 39.0 % of patients 
had AEs leading to dose interruption. Three patients expe-
rienced an SAE, all judged by the local investigator to be 
unrelated to AZD5363. There were no deaths related to 
AEs.
In the 480 mg bid intermittent 4/3 dosing cohort, the 
most common AEs were maculopapular rash (100.0 %), 
diarrhea (83.3 %), and hyperglycemia (83.3 %), with 
66.7 % of patients experiencing at least one AE of CTCAE 
grade ≥3 [hyperglycemia was most frequent (50.0 % of 
patients across all the cohorts)]. One patient in this cohort 
discontinued treatment because of treatment-related AEs of 
rash and drug hypersensitivity, while another patient had an 
SAE of intra-abdominal hemorrhage, which was judged by 
the investigator to be unrelated to treatment.
Overall, there were no obvious trends for changes in 
laboratory parameters, vital signs, ECG parameters, or 
physical examinations compared with baseline during the 
study. One patient in the 360 mg bid 4/3 dosing cohort 
was observed to have elevated glycosylated hemoglobin 
[HbA1c; 5.9 % (baseline) to 8 % (cycle 4) and 7.5 % (cycle 
10)], possibly as a result of mild anemia experienced by the 
patient throughout the study [9].
DLTs were experienced by five patients in the continu-
ous dosing cohorts: one patient in the 240 mg bid cohort 
(grade 3 hypoxia—this event was considered by the inves-
tigator as possibly induced by treatment-related events of 
high fever and maculopapular rash; higher plasma con-
centrations were observed in this patient vs. other patients 
in this treatment cohort), two patients in the 320 mg bid 
treatment group (grade 3 diarrhea in both cases), and two 
patients receiving 400 mg bid (grade 3 diarrhea, and grade 
3 oral mucositis and maculopapular rash). No DLTs were 
reported in any of the intermittent dosing cohorts.
Pharmacokinetics
Following single oral doses, AZD5363 was quantifiable in 
all samples collected across the profile from each patient, 
with the exception of one patient (40 evaluable patients). 
Following Cmax, there was a noticeable distribution phase 
generally lasting up to 6–8 h, consistent with the half-life 
of AZD5363 of approximately 10 h, with an apparent ter-
minal elimination phase established thereafter (Figs. 1, 
2). Exposure data for both single and multiple doses of 
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AZD5363 were generally dose proportional (Table 3). The 
rate of absorption following multiple dosing was consid-
ered to be moderate, with a median (range) tss,max of 1.98 
(0.50–3.97) hours, which was consistent with single-dose 
tmax data of 1.98 (0.87–4.02) hours.
Antitumor activity
The tumor response analysis set included 37 patients with 
a baseline tumor assessment. The best objective response 
according to RECIST version 1.1 is summarized in Table 4. 
Confirmed partial responses were reported by two patients: 
one each in the 480 mg bid intermittent 4/3 and 640 mg bid 
intermittent 2/5 dosing cohorts. At data cutoff, the dura-
tions of partial response for these two patients were 675 
and 127 days, respectively. Ten patients (three on continu-
ous dosing and seven on intermittent dosing) had stable dis-
ease, with durations ranging from 46 to 360 days. Seven of 
these 10 patients had stable disease for 12 weeks or more. 
Disease progression was reported by 48.6 % of patients, 
and no patients had a complete response to AZD5363 
treatment.
Discussion
This phase 1 study was primarily designed to evaluate the 
safety and tolerability of AZD5363 when given at increas-
ing doses and in continuous and intermittent dosing sched-
ules to Japanese patients with advanced solid malignancies. 
Patients were assigned to receive AZD5363 either as con-
tinuous bid dosing (80–400 mg every day) or as intermit-
tent bid dosing (360–480 mg for 4 days/week or 640 mg 
for 2 days/week) in 21-day cycles. Overall, five patients 
(all on continuous dosing) experienced DLTs. MTD was 
not reached in either of the intermittent dosing schedules 
in this study, but given the results from the equivalent 
Western study, no further dosing increase from the MTDs 
Table 1  Patient demographics and baseline characteristics
a Includes cecum and rectal
b Anterior mediastinum, duodenum, endometrium stomale, hypopharyngeal, leimyosarcoma, esophagus, pancreas, stomach, thymus, urinary 
bladder, unknown
Continuous Intermittent
80 mg bid 240 mg bid 320 mg bid 400 mg bid 360 mg bid 4/3 480 mg bid 4/3 640 mg bid 2/5 Total
n 3 7 6 5 8 6 6 41
Mean age (range) 
(years)
55.3 (37–65) 56.1 (43–72) 47.0 (33–63) 51.8 (36–67) 54.4 (38–73) 44.3 (27–64) 55.0 (41–62) 52.0 (27–73)
Males/females  
(n/n)
0/3 3/4 3/3 3/2 4/4 2/4 2/4 17/24
WHO performance 
status [n (%)]
 0 3 (100.0) 5 (71.4) 1 (16.7) 3 (60.0) 3 (37.5) 5 (83.3) 5 (83.3) 25 (61.0)
 1 0 (0.0) 2 (28.6) 5 (83.3) 2 (40.0) 5 (62.5) 1 (16.7) 1 (16.7) 16 (39.0)
Primary tumor site 
[n (%)]
 Breast 1 (33.3) 1 (14.3) 2 (33.3) 0 (0.0) 2 (25.0) 0 (0.0) 2 (33.3) 8 (19.5)
 Lung 0 (0.0) 0 (0.0) 1 (16.7) 1 (20.0) 1 (12.5) 1 (16.7) 1 (16.7) 5 (12.2)
 Uterus 2 (66.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (12.5) 1 (16.7) 1 (16.7) 5 (12.2)
 Pleura 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 2 (25.0) 0 (0.0) 0 (0.0) 3 (7.3)
 Ovary 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 0 (0.0) 1 (16.7) 0 (0.0) 2 (4.9)
 Liver 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 0 (0.0) 1 (16.7) 0 (0.0) 2 (4.9)
 Colorectala 0 (0.0) 2 (28.6) 0 (0.0) 0 (0.0) 1 (12.5) 1 (16.7) 0 (0.0) 4 (9.8)
 Otherb 0 (0.0) 4 (57.1) 2 (33.3) 2 (40.0) 1 (12.5) 1 (16.7) 2 (33.3) 12 (29.3)
Lines of previous 
chemotherapy [n 
(%)]
 1 0 (0.0) 1 (14.3) 0 (0.0) 0 (0.0) 0 (0.0) 2 (33.3) 0 (0.0) 1 (2.4)
 2 1 (33.3) 0 (0.0) 0 (0.0) 1 (20.0) 3 (37.5) 18 (100) 1 (16.7) 8 (19.5)
 ≥3 2 (66.7) 6 (85.7) 6 (100.0) 4 (80.0) 5 (62.5) 4 (66.7) 5 (83.3) 32 (78.1)
 Median 3.0 4.0 4.0 3.0 3.0 3.5 4.0 4.0
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determined for intermittent doses from that study were 
conducted in this study. AEs of CTCAE grade ≥3 caus-
ally related to AZD5363 were more frequent in the 640 mg 
bid intermittent 2/5 dosing cohort than in the 480 mg bid 
intermittent 4/3 dosing cohort (any AE, 83.3 vs. 66.7 %; 
hyperglycemia, 83.3 vs. 50.0 %; diarrhea, 16.7 vs. 0.0 %; 
neutrophil count decreased, 16.7 vs. 0.0 %), indicating 
more favorable tolerability with 480 mg bid intermittent 
4/3 dosing. Intermittent dosing has been advocated as an 
alternative to continuous dosing for oncology therapeutics 
to enable adequate pathway inhibition for efficacy with 
reduced toxicity or receptor reactivation[10].
The primary aim of the study was to determine the 
safety and tolerability of AZD5363 in the target patient 
population. Overall, 97.6 % of patients reported at least 
one AE, the majority (95.1 %) of which was considered 
treatment related. Increased rates of AEs were generally 
observed with increasing dose, irrespective of dosing 
Table 2  Summary of adverse events: number (%) of patients reporting at least one adverse event (frequency >35 %)
a As assessed by the investigator
Continuous Intermittent
80 mg bid 240 mg bid 320 mg bid 400 mg bid 360 mg bid 4/3 480 mg bid 4/3 640 mg bid 2/5 Total
n 3 7 6 5 8 6 6 41
Adverse events (AEs)
 Any 3 (100.0) 6 (85.7) 6 (100.0) 5 (100.0) 8 (100.0) 6 (100.0) 6 (100.0) 40 (97.6)
 Diarrhea 0 (0.0) 5 (71.4) 5 (83.3) 5 (100.0) 7 (87.5) 5 (83.3) 5 (83.3) 32 (78.0)
 Hyperglycemia 0 (0.0) 3 (42.9) 4 (66.7) 5 (100.0) 5 (62.5) 5 (83.3) 6 (100.0) 28 (68.3)
 Nausea 1 (33.3) 3 (42.9) 5 (83.3) 5 (100.0) 3 (37.5) 3 (50.0) 3 (50.0) 23 (56.1)
 Maculopapular rash 0 (0.0) 2 (28.6) 4 (66.7) 5 (100.0) 3 (37.5) 6 (100.0) 3 (50.0) 23 (56.1)
 Decreased appetite 0 (0.0) 2 (28.6) 4 (66.7) 4 (80.0) 5 (62.5) 2 (33.3) 3 (50.0) 20 (48.8)
 Pyrexia 1 (33.3) 4 (57.1) 3 (50.0) 5 (100.0) 3 (37.5) 3 (50.0) 1 (16.7) 20 (48.8)
 Stomatitis 0 (0.0) 3 (42.9) 3 (50.0) 4 (80.0) 3 (37.5) 3 (50.0) 1 (16.7) 17 (41.5)
 Proteinuria 0 (0.0) 0 (0.0) 3 (50.0) 1 (20.0) 3 (37.5) 4 (66.7) 5 (83.3) 16 (39.0)
 Blood creatinine increased 0 (0.0) 2 (28.6) 4 (66.7) 3 (60.0) 2 (25.0) 2 (33.3) 1 (16.7) 14 (34.1)
 White blood cell count 
decreased
0 (0.0) 1 (14.3) 3 (50.0) 1 (20.0) 3 (37.5) 4 (66.7) 1 (16.7) 13 (31.7)
AEs causally related to 
AZD5363a
 Any 3 (100.0) 6 (85.7) 6 (100.0) 5 (100.0) 7 (87.5) 6 (100.0) 6 (100.0) 39 (95.1)
AEs of CTCAE grade ≥3
 Any 0 (0.0) 3 (42.9) 4 (66.7) 5 (100.0) 5 (62.5) 4 (66.7) 5 (83.3) 26 (63.4)
 Hyperglycemia 0 (0.0) 2 (28.6) 2 (33.3) 3 (60.0) 1 (12.5) 3 (50.0) 5 (83.3) 16 (39.0)
 Diarrhea 0 (0.0) 0 (0.0) 3 (50.0) 1 (20.0) 2 (25.0) 0 (0.0) 1 (16.7) 7 (17.1)
 Neutrophil count decreased 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (37.5) 0 (0.0) 1 (16.7) 4 (9.8)
 Lymphocyte count decreased 0 (0.0) 1 (14.3) 1 (16.7) 1 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (7.3)
AEs of CTCAE grade  
≥3 causally related to 
AZD5363a
 Any 0 (0.0) 3 (42.9) 4 (66.7) 5 (100.0) 3 (37.5) 4 (66.7) 5 (83.3) 24 (58.5)
AE with outcome of death
 Any 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
SAE
 Any 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 2 (33.3) 3 (7.3)
SAE causally related to 
AZD5363a
 Any 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AEs leading to discontinua-
tion of AZD5363
 Any 0 (0.0) 1 (14.3) 1 (16.7) 1 (20.0) 0 (0.0) 1 (16.7) 1 (16.7) 5 (12.2)
792 Cancer Chemother Pharmacol (2016) 77:787–795
1 3
regimen, while the frequency of AEs was generally simi-
lar across the dosing schedules. The most common AEs 
experienced by Japanese patients treated with AZD5363 
were diarrhea (78.0 %), hyperglycemia (68.3 %), nausea 
(56.1 %), and maculopapular rash (56.1 %), which is con-
sistent with data for AZD5363 in Western patients [7, 11]. 
Diarrhea resolved during and off AZD5363 treatment in 
91 % of patients who experienced this AE (88 % received 
antidiarrheal treatment), while hyperglycemia appeared to 
be manageable through the use of oral metformin. Rash 
resolved in 58.5 % of patients during and off AZD5363 
treatment. Hyperglycemia is an expected side effect of 
PI3K/AKT/mTOR pathway inhibition given the role 
of the pathway in regulating insulin signaling and glu-
cose homeostasis [12, 13]. Maculopapular rash has been 
observed in clinical studies of other PI3 K/AKT/mTOR 
pathway inhibitors [14]. Although the pathophysiologi-
cal mechanism of drug-induced maculopapular rash is 
unknown, pathway inhibition may induce local cytokine 
and chemokine deregulation, leading to cutaneous toxic-
ity [5].
A secondary objective of the study was to character-
ize the PK of AZD5363. Analysis revealed that the rate 
of absorption following single or multiple bid doses of 
AZD5363 was moderate and appeared to be independent 
of dose. Plasma concentration–time profiles were similar 
across the different dosing schedules. Taking into account 
the small cohort sizes and data variability, the geometric 
mean for Cmax and AUC data was generally dose propor-
tional for the 80- to 640-mg doses. The PK half-life of 
a
b
Fig. 1  Plasma concentration–time profile of single-dose AZD5363 
after a continuous dosing and b intermittent dosing
a
b
Fig. 2  Plasma concentration–time profile after multiple doses (study 
day 8) of AZD5363 for a continuous dosing and b intermittent dos-
ing. *360 mg bid 4 on/3 off and 480 mg bid 4 on/3off; †640 mg bid 2 
on/5 off
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AZD5363 was appropriate for administration by the inter-
mittent dosing regimen. These findings are consistent with 
those of another phase 1 study evaluating AZD5363 in 
Western patients [7].
A further secondary objective was to assess the antitu-
mor activity of AZD5363 by evaluation of tumor response 
using RECIST criteria. Confirmed partial responses were 
experienced by two patients receiving AZD5363. The first 
achieved a partial response 79 days after starting 480 mg 
bid intermittent 4/3 dosing of AZD5363. This 38-year-old 
female patient had primary ovarian cancer (well differen-
tiated, T1N0M0 at diagnosis) with metastatic disease in 
the lung and had received eight prior treatment regimens. 
The patient has achieved continued maintenance of partial 
response (duration of response was 1177 days as of Sep-
tember 2015, according to the investigator), with a best 
response of a 55.8 % decrease in the sum of the longest 
diameter (SLD) of target lesions.
The second patient with long-duration disease control 
had primary estrogen-receptor-positive, HER2-negative 
Table 3  Plasma PK parameters of AZD5363 after a single dose and multiple doses
Data are presented as geometric mean (CV%), apart from thalf, tmax and tss,max, which are presented as median (range)
Continuous Intermittent Total
80 mg bid 240 mg bid 320 mg bid 400 mg bid 360 mg bid  
4/3
480 mg bid  
4/3
640 mg bid  
2/5
Single-dose AZD5363
n 3 7 6 5 8 6 6 41
AUC (ng h/ 
mL)
1265 (26.3) 3293 (39.2) 7109 (115.5) 4666 (20.6) 4772 (69.2) 7208 (46.0) 11390 (41.5) 5184 (86.6)
Cmax (ng/mL) 217 (101.2) 628 (40.8) 1582 (80.2) 1062 (27.9) 1008 (65.5) 1907 (84.7) 2099 (37.1) 1091 (96.3)
thalf (hours) 11.8  
(8.5‒12.2) 10.2  (8.2‒10.9) 9.7 (7.3‒10.6) 9.6 (9.0‒13.0) 9.7 (5.3‒11.1) 9.3 (8.1‒11.6) 10.1  (9.4‒13.7) 9.9 (5.3‒13.7)
tmax (hours) 2 (1‒4) 1.9 (0.87‒2) 1.98 
(0.98‒2.08) 1.97 (0.98‒2.17) 1.99 (0.98‒2.03) 1.025 (0.93‒1.98) 2.015  (1‒4.02) 1.98 (0.87‒4.02)
CL/F (L/h) 63.24 (26.3) 72.89 (39.2) 45.01 (115.5) 85.72 (20.6) 75.45 (69.2) 66.59 (46.0) 56.17 (41.5) 65.57 (57.7)
Vss/F (L) 715.1 (58.9) 682.4 (41.5) 370.2 (97.0) 777.0 (34.1) 680.7 (58.3) 502.2 (63.6) 587.1 (44.2) 594.7 (59.7)
Multiple-dose AZD5363
n 3 7 4 4 7 6 6 37
AUCss (ng h/
mL)
1518 (59.0) 4839 (77.2) 5772 (55.2) 9666 (43.7) 5866 (45.0) 10,930 (33.1) 14,210 (36.7) 6820 (86.0)
Css,max (ng/ 
mL)
318.3 (128.4) 874.4 (89.7) 1222 (53.7) 2094 (56.6) 1366 (64.9) 2670 (36.7) 2618 (20.0) 1430 (96.6)
tss,max (hours) 1 (0.98‒1.97) 1.98  
(0.97‒3.9) 1.465 (0.92‒2.12) 2 (0.93‒2) 0.98 (0.5‒2) 1.99 (1‒2.05) 2.01 (2‒3.97) 1.98 (0.5‒3.97)
CLss/F (L/h) 52.72 (59.0) 49.6 (77.2) 55.44 (55.2) 41.38 (43.7) 61.37 (45.0) 43.9 (33.1) 45.04 (36.7) 49.71 (48.6)
Table 4  Best objective response
a Response confirmed after 4 weeks
Continuous Intermittent Total
80 mg bid 240 mg bid 320 mg bid 400 mg bid 360 mg bid 4/3 480 mg bid 4/3 640 mg bid 2/5
n 3 7 6 5 8 6 6 41
Response
 Complete responsea 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
 Partial responsea 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 1 (16.7) 2 (5.4)
Non-response
 Stable disease ≥6 weeks 2 (66.7) 1 (14.3) 0 (0.0) 0 (0.0) 3 (37.5) 4 (66.7) 0 (0.0) 10 (27.0)
 RECIST progression 1 (33.3) 5 (71.4) 1 (33.3) 3 (75.0) 3 (37.5) 1 (16.7) 4 (66.7) 18 (48.6)
Not evaluable 0 (0.0) 1 (14.3) 2 (66.7) 1 (25.0) 2 (25.0) 0 (0.0) 1 (16.7) 7 (18.9)
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papillary carcinoma breast cancer (non-assessable grade, 
T4N1MX at diagnosis, based on the patient report form) 
with metastatic disease in a mediastinal lymph node and 
the liver on study entry, and had received three chemothera-
peutic regimens and six hormonal therapies prior to study 
entry. The patient, who was assigned to the 640 mg bid 
intermittent 2/5 dosing cohort, achieved a partial response 
at 44 days after starting AZD5363 therapy. However, pro-
gression was confirmed at Day 378, with a best response of 
a 60.8 % decrease in the SLD of target lesions.
The mutation status of both patients who achieved par-
tial responses was analyzed retrospectively (response was 
prospectively investigated as a secondary objective) and 
reported by the investigator. For the first patient, prestudy 
tumor samples from lung metastases were revealed to be 
Akt1 (E17K) and CTNNB1 (G34V) mutation positive. 
Archival primary tumor tissue from the second patient har-
bored an Akt1 (E17K) and TP53 mutation, as well as ampli-
fication of the CCND1 gene. Analysis of archival primary 
tumor samples from the 37 patients in the responder analy-
sis set showed that, of the non-responders, two additional 
patients were identified as PIK3CA mutation positive. In 
contrast to these two treatment responders, two additional 
patients identified as PIK3CA mutation positive did not 
respond to AZD5363 treatment. The E17 K mutation, a 
glutamic acid to lysine substitution, is the most common 
mutation in Akt1, comprising 89 % of the mutation found 
in this gene, and has been shown to constitutively activate 
Akt1, stimulating downstream signaling and transforming 
cells [15]. The results of the current study are consistent 
with findings from non-clinical studies in which AZD5363 
inhibits downstream signaling of Akt1 (E17K) mutation. 
Moreover, the finding that Akt1-mutation-positive tumors 
may be sensitive to AZD5363, whereas PIK3CA-mutation-
positive tumors are relatively insensitive to AZD5363, is 
clinically relevant [5, 15].
A phase 1 study (Study 1, D3610C00001, NCT01226316) 
is currently evaluating the antitumor activity of AZD5363 
monotherapy in patients with tumors harboring the Akt1 
mutations. Two additional studies are investigating AZD5363 
in combination with endocrine therapy and chemother-
apy (FAKTION study [NCT01992952] and PAKT study 
[NCT02423603], respectively) in patients with advanced 
breast cancer.
Conclusions
In Japanese patients with advanced solid tumors, AZD5363 
was generally well tolerated when given in either a con-
tinuous (bid every day) or an intermittent dosing sched-
ule. Based on combined data from preclinical modeling, 
other phase 1 studies, and the current work, the 480 mg bid 
intermittent 4/3 dosing schedule was selected as the mono-
therapy dose for subsequent Phase 1b investigations. Data 
from these studies will provide further insight into whether 
AZD5363 delivers clinical benefit to patients with advanced 
cancer in combination with chemo- or endocrine therapy, 
and as monotherapy in Akt1-mutation-selected patients.
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